NXDC is a privately owned life science company dedicated to the commercial launch of Gleolan in the United States as a real time imaging agent allowing surgeons to visualize brain tumors during surgery.
To bring Gleolan to the surgical community to enhance the upfront management of patients with glioblastoma. The use of Gleolan to visualize structural elements related to tumor presentation and enable the surgeon to make real time decisions about tumor de-bulking has become a standard in other countries and is envisioned to be well received in the US at time of commercial launch.
What We've Achieved
The company received Fast Track Review from the US Food and Drug Administration for its New Drug Application and earned FDA approval in June 2017. NXDC expects the commercial launch of Gleolan in the US during the first half of 2018.